Moleculin Biotech, INC 8-K filings

Moleculin Biotech released an updated corporate presentation on its website on November 14, 2024.

Moleculin Biotech has amended its Phase 3 clinical trial protocol for Annamycin, allowing for an earlier unblinding of data and potentially accelerating the drug's approval timeline.

Moleculin Biotech has secured Institutional Review Board approval to begin its Phase 3 MIRACLE trial for Annamycin in combination with Cytarabine for the treatment of relapsed or refractory acute myeloid leukemia.

Moleculin Biotech has released an investor presentation, providing an update on the company's activities.

Moleculin Biotech reports third quarter 2024 financial results and provides a corporate update, highlighting progress in its Annamycin clinical trials and upcoming Phase 3 study.

Moleculin Biotech will release its financial results for the quarter ending September 30, 2024, on November 8, 2024, followed by a conference call on November 11, 2024.

Moleculin Biotech's stockholders approved the 2024 Stock Plan, elected directors, and ratified the appointment of Grant Thornton LLP as their independent auditor at the 2024 Annual Meeting.

Moleculin Biotech released the transcript of its Virtual Acute Myeloid Leukemia KOL event, emphasizing the potential of Annamycin as a non-cardiotoxic treatment option.

Moleculin Biotech will host a virtual event featuring key opinion leaders to discuss their ongoing Phase 3 clinical trial for Annamycin in treating relapsed or refractory Acute Myeloid Leukemia (AML).

Moleculin Biotech released a new corporate presentation on October 2, 2024, providing an update on the company's activities.

Moleculin Biotech reports positive in vivo efficacy data for Annamycin, showing significant tumor growth inhibition and survival extension in lung cancer models, with high drug concentration in the lungs and no cardiotoxicity.

Moleculin Biotech's CEO, Walter Klemp, discussed the company's Phase 2 clinical trial of a STAT3 inhibitor combined with radiation for glioblastoma treatment in a recent investor segment.

Moleculin Biotech, Inc. has released a new corporate presentation, which is now available on the company's website.

Moleculin Biotech has initiated a Phase 2 clinical trial evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma, with the first patients now enrolled and treated.

Moleculin Biotech has successfully closed a public offering, raising $5.5 million upfront with the potential for an additional $11 million upon full exercise of milestone-linked warrants.

Moleculin Biotech has priced a public offering expected to raise $5.5 million initially, with the potential for an additional $11 million upon full exercise of warrants.

Moleculin Biotech is moving forward with a pivotal Phase 3 clinical trial for Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) after a positive meeting with the FDA.

Moleculin Biotech is advancing Annamycin, in combination with Cytarabine, to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy.

Moleculin Biotech will host a webcast to discuss its plans to advance Annamycin in combination with Cytarabine to a Phase 3 pivotal trial for the treatment of AML patients.

Moleculin Biotech, Inc. has released a new corporate presentation, which is available on the company's website.

Moleculin Biotech has announced plans to proceed with a Phase 3 clinical trial for Annamycin in combination with cytarabine for relapsed or refractory AML, following a positive meeting with the FDA.

Moleculin Biotech has completed its End of Phase 2 meeting with the FDA regarding its Annamycin clinical trial for AML, with positive remission rates reported.

Moleculin Biotech released a new corporate presentation on June 18, 2024, providing an update on the company's activities.

Moleculin Biotech reports encouraging preliminary results from its Phase 1B/2 trial of Annamycin in combination with Cytarabine for acute myeloid leukemia (AML), showing significant efficacy and no cardiotoxicity.

Moleculin Biotech's abstract on Liposomal Annamycin for acute myeloid leukemia treatment has been accepted for a poster presentation at the European Hematology Association 2024 Hybrid Congress.

Moleculin Biotech has commenced a Phase 2 clinical trial, funded by the NIH, to evaluate WP1066 in combination with radiation therapy for the treatment of glioblastoma.

Moleculin Biotech, Inc. has released a new corporate presentation, which is available on the company's website.

Moleculin Biotech reports promising interim clinical trial results for Annamycin in acute myeloid leukemia (AML) and provides a financial update for the first quarter of 2024.

Moleculin Biotech reports promising interim clinical data for Annamycin in AML and provides a financial update for the first quarter of 2024.

Moleculin Biotech has received a patent issue notification for its liposomal Annamycin delivery technology, which is expected to provide composition protection until 2040.